Selected Cases

Antitrust

• Alta Bates and Summit Medical Centers Merger Antitrust Suit
• Brand Name Prescription Drug Litigation
• Federal Trade Commission v. Mylan Laboratories
• HDC Medical, Inc. v. Minntech Corp
• Louisiana Wholesale Drug Co., Inc. v. Sanofi-Aventis
• Organon v. Mylan Pharmaceuticals
• Pre-Merger Investigation of Medtronic Acquisition
• Sample v. Monsanto Company
• Steward Health Care System Acquisition
• University of California Medical Center at San Francisco - Stanford Health Care Merger Review
• Vitamins Antitrust Litigation
• Wichita Clinic v. Columbia-HCA Health Services of Kansas

Breach of Contract and Fraud

• Hospital-Payer Billing Disputes
• In re Managed Care Litigation
• Justice Department Investigation into Health Care Fraud
• Pharmaceutical Off-Label Promotion Settlements
• U.S. Department of Justice v. Tenet Healthcare Corporation

Intellectual Property Rights

• Applied Medical Resources Corp. v. United States Surgical Corp. (Covidien)
• Assessing Adverse Events
• Assessing Health Care Patent Infringement Claims
• Bavarian Nordic v. Acambis, PLC (Inv. No. 337-TA-550)
• Berlex v. Biogen
• Bone Care International v. Roxane Labs, et al.
• Elan Corporation v. Andrx Pharmaceuticals
• Elan Pharma International, Ltd. v. Abraxis BioScience, Inc.
• Galderma Laboratories et al. v. Tolmar, Inc.
• Igen International v. Roche Holding AG
• In re Abbott Laboratories Coronary and Peripheral Stent Litigations
• Innogenetics NV v. Abbott Laboratories
• LifeWatch Services, Inc. v. Medicomp, Inc.
• Medtronic MiniMed, Inc. v. Nova Biomedical Corp.
• Mylan Pharmaceuticals v. Procter & Gamble Co.
• Ortho-McNeil v. Mylan
• Otsuka Pharmaceutical Co. Secures Patent Victory at Trial
• Regents of the University of California v. Genentech
• St. Jude Medical, Inc. v. Access Closure, Inc.
• Stanford v. Roche Molecular Systems
• Tyco Healthcare Group LP, et al. v. Ethicon Endo-Surgery, Inc.
• Valuation of Intellectual Property in the Health Care Industry

Mass Torts and Product Liability

• Assessment of Excess Risk for Causation Analysis
• AstraZeneca v. Tap Pharmaceuticals, Inc.
• Bracco Diagnostics, Inc. v. Amersham Health, Inc.
• Compilation and Analysis of Plaintiff Medical Records
• Confidential Ongoing Pharmaceutical Mass Tort Matter
• Development of a Framework for Litigation Decision Making
• Economic Assistance in Connection with Class Certification
• Extrapolating from Proposed Payout Matrices to Assess Overall Exposure
• Identification of the Timing of Adverse Events Relative to Drug Use
• Steadfast Insurance Company v. Purdue Frederick Company

Securities Fraud

• Biotechnology Firm 10b-5 Matter – Human Testing
• Biotechnology Firm 10b-5 Matter – Phase III Testing
• Biotechnology Stock Drop Matter
• Confidential Ongoing Pharmaceutical 10b-5 Matters
• Securities and Exchange Commission v. Biopure Corporation, et al.

Transfer Pricing and Tax Issues

• GlaxoSmithKline Holdings (Americas) Inc. v. Commissioner of the IRS
• SmithKline v. Revenue Canada

Health Outcomes

• Analysis of ROI for Bariatric Surgery
• Comparison of Escitalopram and Citalopram
• Cost Comparison of Painful Conditions
• Costs Associated with ADHD Patients and Families
• Economic Burden of Opioid Abuse
• Effects of Depression Relative to Other Health Problems
• Quantifying the Economic Burden of Depression

Drug Safety and Epidemiology

• Assessing Potential Drug Safety Issues for a Major Pharmaceutical Company
• Documenting the Need for Care Management in Elderly Hypertensive Patients
• Epidemiology Studies on Rare Childhood Cancers
• Epidemiology Studies on Spinal Cord Injury
• Impact of Aromatase Inhibitors on Bone Loss in Breast Cancer Patients
• Studies of Adverse Events
• Studies to Assess Incidence of Renal Injury in Cancer Patients Using Bisphosphonates
• Study of Safety and Efficacy of VEGF Inhibitors in Actual Use

Commercial Strategies

• Achieving Commercial Results in Managed Markets
• Authorized Generics, Competition, and Consumer Prices
• Cardiovascular Acquisition Analysis
• Determining Product Value Proposition
• Developing a Comprehensive Product Strategy
• Developing a Growth Strategy Under Constraints
• Developing a New Drug Value Profile to Inform Clinical Trials
• Establishing a Health Outcomes Organization
• Identifying and Benchmarking Acquisition Targets
• Investment and Acquisition Strategy
• Modeling the Economics of Growth Opportunities
• Pipeline Development
• Priority Customer Segmentation Strategy
• Refining Contracting Strategies in the Face of Competition
• Strategies for Patent Expiration and Lifecycle Management
• Using Sensitivity Analysis to Drive Pricing Strategy
• Value of Pharmaceuticals to Society